Receptor pharmacology

Established Concentrated 7-OH is best understood first as a high-potency μ-opioid receptor (MOR) agonist. Potency asks how much ligand produces a measured effect; intrinsic efficacy asks how strongly the bound ligand activates a pathway in the conditions of that experiment. Those are different questions, and neither is a bedside dose conversion. ^E12E15

Earlier low-reserve and β-arrestin/BRET systems characterised 7-OH as a partial agonist, while a broader human-receptor study found much higher maximal cAMP effects in some configurations, approaching the reference agonist response. Receptor density, readout, amplification, and cellular context change the answer. ^E12E15

The label matters because “partial agonist” is often heard as a safety certificate. It is not. A partial result in one model cannot establish a general ceiling on respiratory toxicity, dependence, withdrawal, variable commercial formulations, or harm from sedative co-exposures. Direct respiratory work and a human arrest report make that clinical caution non-negotiable. ^E23E24

The inclusion rule here is deliberately strict: demonstrated functional activation by a characterised alkaloid or metabolite, not docking, displacement, a computational prediction, or a behavioural effect alone. The resulting diagram is smaller than many kratom diagrams, but clinically more useful.

Emerging MOR is the core clinical pathway. KOR and DOR should be shown as secondary, visibly qualified pathways—not as equal arrows and not as a single unqualified agonist label. The disagreement across studies reflects different receptor expression and different cAMP, GTP-gamma-S, β-arrestin, BRET, and tissue readouts; that is a limitation of translation, not a reason to hide the disagreement. ^E12E15

“Kratom” is not a single pharmacological exposure. Mitragynine is a botanical parent alkaloid with lower potency and often lower efficacy at MOR than 7-OH; 7-OH is the potent oxidised metabolite and minor alkaloid concentrated in the products at issue. Mitragynine pseudoindoxyl is a further active product demonstrated in pooled human plasma ex vivo, with greater opioid potency and efficacy in the reported receptor work. ^E12E15E18

Many kratom alkaloids show G-protein-favouring signalling with limited β-arrestin-2 recruitment in cell systems. That is real pharmacology and may alter a ligand’s profile relative to conventional opioids. It does not prove that a high-dose 7-OH product cannot depress respiration or produce opioid toxicity in people. ^E12E15

Mechanistically plausible Signalling bias may help explain differences across ligands, but its clinical effect at real-world exposures remains unknown. In rat respiratory work, 7-OH reduced respiratory rate, tidal volume, and minute ventilation; naloxone reversed the depression. A published human case described cardiopulmonary arrest after reported 7-OH use with naloxone-associated revival. ^E23E24

Two non-opioid pathways meet the strict functional-activation standard, but both belong in a secondary botanical-kratom layer rather than in the core 7-OH diagram. The 9-O-desmethyl metabolites of speciogynine and paynantheine activate 5-HT_1A in tested systems. Mitragynine is a low-potency α_1A partial agonist and an α_2A antagonist in recent functional work. ^E13E14

Those findings may contribute to the mood, autonomic, or stimulant-like experience of botanical kratom. They do not establish that direct purified 7-OH is clinically serotonergic or adrenergic, and they do not justify calling withdrawal a proven serotonergic syndrome. ^E13E14

The discarded claims are clinically useful: they prevent a diagram from turning binding observations into a false explanation for agitation, mood symptoms, or treatment response. ^E12E13E14

The opioid component is real: concentrated 7-OH provides potent MOR activity, and repeated use can produce reinforcement, physical dependence, and opioid-type withdrawal. Its short, repetitive use pattern can make interdose symptoms and nocturnal redosing central to the history. ^E12E25

Three further features complicate the presentation. First, botanical exposure may carry slower mitragynine kinetics and non-opioid alkaloid effects. Second, 5-HT_1A-active metabolites and low-potency α_1A activity offer a credible mechanism for additional affective, sleep, and autonomic features in whole-plant exposure—without proving that direct 7-OH is serotonergic. Third, KOR involvement is a plausible but unproven contributor to dysphoria and anhedonia. ^E12E13E14

For a patient using a concentrated product, document the product form, labelled ingredients, route, frequency, overnight use, prior attempts to stop, co-ingestants, and whether leaf, extracts, tablets, films, or multiple products are involved. The pharmacology supports treating this as an atypical opioid exposure, not as a benign-herbal-versus-opioid argument. ^E09E10E12

Receptor nuance should widen assessment, not produce false precision about cross-tolerance or induction timing. Direct high-dose purified-7-OH human pharmacokinetics and a validated withdrawal clock are not available. Buprenorphine planning should therefore be individualised to convincing clinical withdrawal and the product history; no fixed safe hour follows from this receptor map. See the withdrawal and treatment module.